Transplant/Artificial Liver
Liver Transplant - HCV
AASLD 2013: Hepatitis C Treatment Reduces Liver Cancer and Death, But Most Remain Untreated
- Details
- Category: HCV Disease Progression
- Published on Wednesday, 13 November 2013 00:00
- Written by Liz Highleyman
Hepatitis C treatment that leads to viral suppression significantly reduces the likelihood of liver disease progression and liver-related mortality, but most patients remain untreated, according to a presentation at the 64th AASLD Liver Meeting last week in Washington, DC. Other studies found that a growing proportion of liver transplants are due to hepatocellular carcinoma, which can still occur even after treatment.
AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 November 2013 00:00
- Written by Janssen
Simeprevir added to pegylated interferon and ribavirin performed well in difficult-to-treat treatment-naive patients and prior relapsers with genotype 1 chronic hepatitis C, according to 2 poster presentations at the 64th AASLD Liver Meeting last week in Washington, DC, as described in an announcement by Janssen.
Human Stem Cells Used to Create Functional Liver Cells in Mice
- Details
- Category: Liver Transplant - HBV
- Published on Wednesday, 07 August 2013 00:00
- Written by Liz Highleyman
Researchers have discovered a way to generate functional hepatocytes (liver cells) from human stem cells, which worked as expected and increased survival when transplanted into mice with acute liver injury, researchers reported in the July 9, 2013, advance online edition of Stem Cells and Development.
AASLD 2013: Sofosbuvir Taken Before or After Liver Transplant Reduces HCV Recurrence
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 08 November 2013 00:00
- Written by Liz Highleyman
An interferon-free combination of sofosbuvir plus ribavirin administered before liver transplantation prevented hepatitis C recurrence in nearly two-thirds of patients, while the same regimen led to early viral clearance in three-quarters of those treated after transplantation, according to studies presented this week at the 64thAASLD Liver Meeting in Washington, DC.
EASL 2013: Anemia Is a Common Side Effect of First-generation HCV Protease Inhibitors
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
About half of patients taking boceprevir (Victrelis) or telaprevir (Incivek or Incivo) developed anemia and approximately one-third experienced skin rash, but sustained response rates were high in an analysis of a population representative of people with chronic hepatitis C in North America, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
More Articles...
- EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects
- Milk Thistle Drug May Help Control HCV Replication after Liver Transplant
- Everolimus (Zortress) Approved to Prevent Liver Transplant Rejection
- Researchers Grow Liver Tissue from Pluripotent Stem Cells
Web Design and Development by